SEC Form 4 · accession 0000899243-15-007649
KERYX BIOPHARMACEUTICALS INC · KERX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Scott A Holmes
Officer — Chief Financial Officer
Period of report
Nov 3, 2015
Accepted (ET)
Nov 5, 2015 · 5:01 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001114220
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Nov 3, 2015 | P | 3,672 | $5.299 | A | 58,414 | D | |
| Common StockF2 | Nov 4, 2015 | P | 1,328 | $5.40 | A | 59,742 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Mr. Holmes effected multiple same-way open market purchase transactions on the same day at different prices, ranging from $5.29 to $5.30, through a trade order executed by a broker-dealer. The price reported in Column 4 is a weighted average price. The reporting person has reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price.
- F2Includes 45,000 shares of restricted stock.